GLAND Gland Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Gland Pharma delivered a strong Q3 FY26, characterized by robust volume-led growth in the US and a successful EBITDA turnaround at Cenexi. While US pricing saw a 5-6% erosion, it was more than offset by a 19% volume surge and internal cost efficiencies. The company is pivoting toward high-end CDMO work, evidenced by a new $25-30 million oncology contract and significant capacity expansion in cartridges and biologics.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 16.5%, net profit up 4.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 1,063 | 1,011 | 1,030 | 1,039 | 1,074 +1% | 1,178 +17% |
| EBITDA | 364 | 391 | 394 | 359 | 375 +3% | 422 +8% |
| Net profit | 282 | 295 | 290 | 269 | 302 +7% | 308 +4% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
